Abstract
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
Younes A.
Bartlett N.L.
Leonard J.P.
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas . N Engl J Med. 2010 ; 363 (19 ): 1812 –1821 .
2.
Foyil K.V.
Bartlett N.L.
Brentuximab vedotin for the treatment of CD30+ lymphomas . Immunotherapy. 2011 ; 3 (4 ): 475 –485 .
3.
Fanale M.
Bartlett N.K.
Forero-Torres A.
The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study . Proc Am Soc Hematol. 2010 ; abstract 2731. http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/2731?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=brentuximab&searchid=1&FIRSTINDEX=0&volume=114&issue=22&resourcetype=HWCIT. Accessed September 10, 2011.
4.
Chen R.
Gopal A.K.
Smith S.E.
Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma . Proc Am Soc Hematol. 2010 ; abstract 283. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/283?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=brentuximab&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT. Accessed September 10, 2011.
5.
Shustov A.R.
Advani R.
Brice P.
Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma . Proc Am Soc Hematol. 2010 ; abstract 961. http://abstracts.hematologylibrary.org/cgi/content/abstract/116/21/961?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=brentuximab&searchid=1&FIRSTINDEX=0&volume=116&issue=21&resourcetype=HWCIT. Accessed September 10, 2011.
6.
Chen R.W.
Gopal A.K.
Smith S.E.
Results from a pivotal phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL) . Proc Am Soc Clin Oncol. 2011 ; abstract 8031. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76520. Accessed September 10, 2011.
7.
Pro B.
Advani R.
Brice P.
Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) . Proc Am Soc Clin Oncol. 2011 ; abstract 8032. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&xonfID=102&abstractID=76562. Accessed September 10, 2011.
8.
Bartlett N.
Grove L.E.
Kennedy D.A.
Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: a case series . Proc Am Soc Clin Oncol. 2010 ; abstract 8062. http://www.asco.org/portal/site/ASCOv2/template.RAW/menuitem.alc60e38cd6d5b9f01ae0094ef37a01d/?Javax.portlet.tpst=b2e033002b246c2828a46427ef37a01d_ws_RW&javax.portlet.prp_b2e033002b246c2828a46427ef37a01d_viewID=abst_detail_rawview&javax.portlet.begCacheTok=com.vignette.cachetoken&javax.portlet.endCacheTok=com.vignette.cachetoken&index=n&confID=74&abstractID=50913. Accessed September 10, 2011.
9.Adcetris. Seattle Genetics, Inc , Bothell, WA, USA. http://www.adcetris.com/_pdf/Adcetris_USPI_2011.pdf. Accessed September 10, 2011.
10.
Chapman P.B.
Hauschild A.
Robert C.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation . N Engl J Med. 2011 ; 364 (26 ): 2507 –2516 .
11.
Ribas A.
Kim K.B.
Schuchter L.M.
BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma . Proc Am Soc Clin Oncol. 2011 ; abstract 8509. http://www.asco.org/ASCOv2/Meetings/Abstracts?vmview=abst_detail_view&xonfID=102&abstractID=84075. Accessed September 10, 2011.
12.
Kim K.B.
Flaherty K.T.
Chapman P.B.
Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM) . Proc Am Soc Clin Oncol. 2011 ; abstract 8519. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&:confID=102&abstractID=82560. Accessed September 10, 2011.
13.
Dummer R.
Rinderknecht J.
Goldinger S.M.
An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases . Proc Am Soc Clin Oncol. 2011 ; abstract 8548. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&:confID=102&abstractID=80295. Accessed September 10, 2011.
14.Zelboraf. Genentech USA, Inc , South San Francisco, CA, USA. http://www.gene.com/gene/products/information/zelboraf/pdf/pi.pdf. Accessed September 10, 2011.